Ozempic isn't known to harm the prostate, and early research leans the other way. A 2025 meta-analysis of five studies linked GLP-1 drugs such as semaglutide to a 28% lower prostate cancer risk, though no trial has proven they prevent it. One database study did find more erectile dysfunction in non-diabetic men taking semaglutide.
Ozempic and the prostate at a glance:
| Question | Short answer |
|---|---|
| Does it cause prostate problems? | No prostate side effects are listed in its FDA prescribing information |
| Prostate cancer risk | Lower in observational studies (28% in a 2025 meta-analysis), not proven by a trial |
| Enlarged prostate (BPH) | Not a treatment; weight loss may ease urinary symptoms |
| PSA readings | Not studied on GLP-1 drugs; body weight is known to affect PSA |
| Peeing more | Not a diuretic; the label's concern is dehydration from nausea, vomiting, or diarrhea |
| Erectile dysfunction | 1.47% vs. 0.32% of non-diabetic men in one 2024 study, about 4.5 times the rate |
| Taking BPH pills too | No listed interaction, but it slows stomach emptying and both can cause dizziness |
What Do Ozempic and Other GLP-1 Drugs Do to the Prostate?
As far as current research shows, nothing harmful. Ozempic's FDA prescribing information lists no prostate side effects, and a 2026 review of urology research found signals of lower prostate cancer risk in population studies. The open questions are about erectile function, PSA readings, and how these drugs work alongside prostate pills.
Ozempic is semaglutide, a GLP-1 receptor agonist. It copies a gut hormone that helps release insulin, slows how fast the stomach empties, and reduces appetite. The FDA approved it for adults with type 2 diabetes. Wegovy, Mounjaro, and Zepbound belong to the same family.
Most of what we know about the prostate comes from large health records of men with diabetes, not from trials built to study the prostate. That's why the review's author, a German urologist, called for "prospective controlled trials with urological endpoints." Each section below separates what the studies found from what is still a guess.
Does Ozempic Lower Prostate Cancer Risk?
It may, but that isn't proven. A 2025 meta-analysis of five studies found a 28% lower prostate cancer risk in men using GLP-1 drugs, compared with placebo or other diabetes medicines (relative risk 0.72). All five were observational, so healthier habits or other differences between the groups could explain part of the gap.
lower
Across five studies, men taking GLP-1 drugs were diagnosed with prostate cancer about 28% less often than men on placebo or other diabetes medicines. The authors called the link "protective" but said more research is needed.Source: Sharma et al., International Urology and Nephrology (2025)
We compiled the two largest single studies here, because they show how much the result depends on the comparison:
| Study | Men studied | Compared with | Result |
|---|---|---|---|
| UK records, 2022 | 5,063 starting a GLP-1 drug | 112,955 starting a sulfonylurea | 35% lower risk (hazard ratio 0.65) |
| Denmark, 2023 (men 50+) | 14,206 starting a GLP-1 drug | 21,756 starting basal insulin | 9% lower overall, a gap that could be chance (0.91); 44% lower in men 70+ (0.56) |
Lab work points the same way. In a 2025 study from the University of Illinois Chicago, semaglutide slowed the growth of prostate cancer cells, alone and with the prostate cancer drug enzalutamide. Results in cells often don't carry over to people, though. No GLP-1 drug is approved to prevent prostate cancer, so the usual screening advice doesn't change.
Can You Take Ozempic After Prostate Cancer?
Often, yes. Nothing in Ozempic's FDA label rules out men with a history of prostate cancer; its boxed cancer warning concerns a rare thyroid tumor. Hormone therapy for prostate cancer often brings heart and metabolic problems, and a 2026 study of men with diabetes on that therapy linked GLP-1 use to lower death rates. Your oncologist should weigh in first.
That 2026 study, from Taiwan, followed men with prostate cancer and type 2 diabetes who were on hormone therapy. After matching 659 men in each group, those taking a GLP-1 drug had a 40% lower death rate from any cause than men taking a DPP-4 inhibitor, another diabetes pill (hazard ratio 0.60). It was observational, so it shows a link, not proof.
A team at MD Anderson Cancer Center has laid out the case for clinical trials of GLP-1 drugs in men with prostate cancer, and at least four are already registered on ClinicalTrials.gov, including tests before surgery and during hormone therapy (checked November 2026). Until results arrive, two practical points come from the FDA label:
- Thyroid history: Ozempic isn't for men with a personal or family history of medullary thyroid cancer or a condition called MEN 2.
- Procedures with sedation: food can stay in the stomach longer, and pulmonary aspiration has been reported during anesthesia. Tell the team before a biopsy or prostate surgery.
Can Ozempic Shrink an Enlarged Prostate?
No study has shown that it does, and it isn't approved for an enlarged prostate (BPH). The link runs through weight: in a 2015 meta-analysis of 5,403 men, those with metabolic syndrome had prostates about 1.8 mL larger. Weight-loss surgery improved urinary symptom scores in a 2021 review, so a GLP-1 drug might help indirectly.
That 2021 review pooled seven studies of 334 men. On average, their symptom score dropped by 2.82 points after surgery. In one of those studies, the improvement tracked better insulin resistance more closely than the number of pounds lost, which fits what we know about what causes an enlarged prostate.
More direct evidence may be on the way. At the American Urological Association's 2026 meeting, researchers presented a nationwide insurance-claims study on whether GLP-1 use changes how often men with BPH go on to need surgery. Its full results haven't been published in a journal yet (checked November 2026).
Weight loss is a reasonable goal on its own, but it doesn't replace BPH treatment. If urinary symptoms bother you, our enlarged prostate guide covers the medicines and procedures that have been tested for BPH itself.
Does Ozempic Change Your PSA Level?
No published study has measured PSA in men starting Ozempic, as far as we found in November 2026. Body weight does matter: in a JAMA study of 13,634 men treated for prostate cancer, heavier men had lower PSA readings, likely because their larger blood volume diluted the same amount of PSA. Mention big weight changes before a PSA test.
In theory, a lower reading caused by extra blood volume could drift as weight comes off, but nobody has measured that on GLP-1 drugs. What matters most is the trend over time, read by someone who knows your history. Our guide to PSA levels by age explains the ranges, and what happens at a PSA test covers other things that can nudge the number.
Does Ozempic Make You Pee More?
Not directly. Ozempic isn't a diuretic, and its FDA label doesn't list frequent urination as a side effect. Many people pee more simply because they're told to drink extra water. In men with diabetes, better blood sugar control may even help, since the NIH lists increased urination as a common symptom of diabetes itself.
The label's real concern runs the other way. Nausea, vomiting, and diarrhea are common, especially when the dose goes up, and they can dehydrate you. The label reports acute kidney injury after dehydration, in some cases needing dialysis. If you can't keep fluids down, call your doctor.
If you're getting up at night more often, an enlarged prostate is a more likely cause than the drug. Our article on why you may pee so much at night goes through the common causes. Being unable to urinate at all is different: the NIH says to get medical help right away.
Does Ozempic Cause Erectile Dysfunction?
It might in some men, though the evidence is limited. A 2024 database study of 3,094 non-diabetic men aged 18 to 50 found new erectile dysfunction in 1.47% of those prescribed semaglutide, versus 0.32% of similar men who weren't. That's about 4.5 times the rate, but the study can't prove semaglutide was the cause.
Other research points the other way. A 2025 meta-analysis of four small studies found GLP-1 drugs raised bioavailable testosterone, and the 2026 urology review described better erectile function in men whose low testosterone was tied to obesity. Erectile dysfunction isn't listed in the FDA labels for Ozempic or Wegovy that we checked.
If you notice a change, bring it up rather than stopping the medicine on your own. Your doctor can also check for other common causes.
Are Wegovy, Mounjaro, and Zepbound Any Different?
Wegovy is the same drug as Ozempic, semaglutide, approved for weight management and heart risk rather than diabetes. Mounjaro and Zepbound contain tirzepatide, which acts on two gut hormones, GIP and GLP-1, instead of one. Most prostate research so far covers semaglutide and older GLP-1 drugs, so the data on tirzepatide are thinner.
The approved drugs in this family can bring weight loss of up to 22% of body weight, according to the 2026 urology review. Mounjaro is approved for type 2 diabetes, and Zepbound for weight management and obstructive sleep apnea. All four slow stomach emptying, so the advice about pills and procedures above applies to each of them.
What Should You Ask Your Doctor Before Starting?
Start with your prostate history: any BPH medicine you take, your last PSA result, and any past prostate cancer treatment. A 2026 review urged urologists to keep a closer eye on men taking GLP-1 drugs and to talk through urinary, sexual, and surgery-related effects. These questions can help you start that conversation:
- I take a pill for my prostate. Does the timing need to change while my stomach empties more slowly?
- Should we check my PSA before I lose a lot of weight, so we have a baseline?
- I'm being treated for prostate cancer. Does my oncologist agree with this plan?
- I have a procedure coming up. When should the team know I'm on this drug?
- What should I do if I notice changes in my erections?
Frequently asked questions
Does Ozempic mess with your prostate?
There's no sign that it does. Prostate problems aren't among the side effects in Ozempic's FDA prescribing information, and population studies point to a lower, not higher, prostate cancer risk in men taking GLP-1 drugs. If urinary symptoms change after you start, have them checked like any new symptom, because they may have another cause.
Can losing weight reverse an enlarged prostate?
No study has shown that weight loss shrinks an enlarged prostate, but it can ease symptoms. In a 2021 review of seven studies with 334 men, urinary symptom scores improved after weight-loss surgery. One study tied the gain more to better insulin resistance than to the pounds lost. BPH medicines remain the standard treatment.
Is it normal to pee more when taking GLP-1?
It's common to notice, but it isn't a direct drug effect. GLP-1 drugs aren't diuretics, and Ozempic's FDA label doesn't list frequent urination. Drinking more water explains much of it. Peeing much less than usual matters more, because vomiting or diarrhea can dehydrate you and, in rare cases, injure the kidneys.
Can I take Ozempic with Flomax (tamsulosin)?
Usually, but ask your doctor or pharmacist first. Ozempic's FDA label doesn't list tamsulosin as an interaction, but it slows stomach emptying, which can change how pills are absorbed. Both can also cause dizziness: tamsulosin when you stand up quickly, and in Wegovy trials, low blood pressure in 1.3% of adults versus 0.4% on placebo.
Can a urologist prescribe GLP-1?
Yes. In the US, GLP-1 drugs are prescription medicines, and their FDA labels don't limit them to one specialty, so any clinician licensed to prescribe, a urologist included, can write one. A 2026 review urged urologists to follow men on these drugs closely and to explain urinary, sexual, and surgery-related effects.
Elizabeth Miller
Elizabeth founded The Prostate Post after watching her husband deal quietly with prostate and urinary symptoms for a long time before he was willing to try anything for it. She personally researches every ingredient and study cited on this site, checking marketing claims against the primary literature. She is not a doctor. Nothing here replaces medical advice.
Sources
- Zentralblatt für Chirurgie: Klotz T. "GLP-1 Receptor Agonists in Urology and Andrology: Indications, Opportunities and Clinically Relevant Adverse Effects" (2026, in German)
- International Urology and Nephrology: Sharma N, et al. "Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis", 5 studies (2025)
- Epidemiology: Lu S, et al. "Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients With Type 2 Diabetes" (2022)
- Diabetologia: Skriver C, et al. "Potential preventive properties of GLP-1 receptor agonists against prostate cancer: a nationwide cohort study" (2023)
- Endocrine-Related Cancer: Bera S, et al. "GLP1 receptor agonism alters growth and therapeutic response in prostate cancer" (2025)
- Frontiers in Urology: Huang SC, et al. "Glucagon-like peptide-1 receptor agonist versus other anti-diabetic agents on patients with prostate cancer undergoing androgen-deprivation therapy" (2026)
- Urology: Fang A, et al. "GLP-1 Agonist Use Among Men With Localized Prostate Cancer: A Narrative Review and Rationale for Prospective Clinical Trials" (2025)
- ClinicalTrials.gov (NIH): registered trials of GLP-1 drugs in prostate cancer (NCT07727473, NCT06908694, NCT06759701, NCT07202247), checked November 2026
- BJU International: Gacci M, et al. "Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis" (2015)
- Obesity Surgery: Stefanova I, et al. "Systematic Review and Meta-Analysis of the Impact of Bariatric Surgery on Lower Urinary Tract Symptoms in Males" (2021)
- American Urological Association 2026 Annual Meeting: abstract IP15-19, "Association Between Glucagon-Like Peptide-1 Agonist Use and Escalation to Surgical Treatment for Benign Prostatic Hyperplasia: A Nationwide Claims Database Study", presented May 2026; full results not yet published (checked November 2026)
- BJU International: Luke S, et al. "Effects of bariatric surgery on untreated lower urinary tract symptoms: a prospective multicentre cohort study" (2015)
- JAMA: Bañez LL, et al. "Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer" (2007)
- International Journal of Impotence Research: Able C, et al. "Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study" (2024)
- BMC Urology: Orra SH, et al. "Effect of GLP-1 agonists on testosterone levels: a systematic review and meta-analysis" (2025)
- FDA prescribing information via DailyMed (NIH): Ozempic (semaglutide) injection, checked November 2026
- FDA prescribing information via DailyMed (NIH): Wegovy (semaglutide), checked November 2026
- FDA prescribing information via DailyMed (NIH): Zepbound (tirzepatide), checked November 2026
- MedlinePlus (NIH): "Tamsulosin"
- NIH National Institute of Diabetes and Digestive and Kidney Diseases: "Symptoms & Causes of Diabetes"
- NIH National Institute of Diabetes and Digestive and Kidney Diseases: "Prostate Enlargement (Benign Prostatic Hyperplasia)"
Medical disclaimer: The Prostate Post is an independent publication. Our content is for informational purposes only and is not medical advice, diagnosis, or treatment. Never start, stop, or change a prescription medicine such as Ozempic without talking to the doctor who prescribed it. Statements about dietary supplements have not been evaluated by the Food and Drug Administration; supplements are not intended to diagnose, treat, cure, or prevent any disease.